Trial Profile
A Randomised, Placebo-controlled, Multicentre Phase IIb Study Evaluating the Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Pirepemat (Primary)
- Indications Dementia; Parkinson's disease
- Focus Therapeutic Use
- Acronyms React-PD
- Sponsors Integrative Research Laboratories
- 27 Feb 2024 According to a IRLAB Therapeutics media release, abstract from this study has been accepted and will be presented at the scientific conference AD/PD™ 2024: 18th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Lisbon, Portugal, on March 5-9, 2024.
- 12 Dec 2023 According to a IRLAB media release, The study is active at 38 study sites across France, Germany, Poland, the Netherlands, Spain, and Sweden and it will identify the optimal dose for Phase III.
- 17 Jul 2023 According to an IRLAB media release, company announced that the independent Data and Safety Monitoring Board (DSMB), after review (from the initial 25 patients participating in the study) of safety and the integrity of data unanimously recommends that the Phase IIb study continues.